Nanocatalytic Mitochondrial Oxidative Stress Amplification and Mitophagy Disruption for Efficient Tumor Catalytic Therapy

Why It Matters

By simultaneously amplifying mitochondrial oxidative stress and disabling the cell’s protective mitophagy, the platform achieves higher tumor kill rates with potentially lower systemic toxicity, advancing nanocatalytic cancer therapeutics.

Key Takeaways

• Mitochondria-targeted Co‑SA‑TPP@CQ nanocatalyst synthesized.
• Generates superoxide and O2, amplifying oxidative stress.
• Chloroquine blocks mitophagy, preventing mitochondrial clearance.
• Dual mechanism induces tumor cell apoptosis efficiently.
• Provides precision nanocatalytic therapy with reduced off‑target effects.

Pulse Analysis

Nanocatalytic cancer therapy has emerged as a promising alternative to conventional chemotherapy, yet its clinical translation is hampered by delivery inefficiencies and off‑target effects. Targeting subcellular organelles, especially mitochondria, offers a route to amplify therapeutic potency because these organelles control cellular metabolism and apoptosis. Recent advances in single‑atom catalysis enable precise redox reactions at the nanoscale, positioning them as ideal tools for generating reactive oxygen species directly within malignant cells.

The Co‑SA‑TPP@CQ platform leverages an ultrasmall cobalt single‑atom catalyst functionalized with triphenylphosphine to achieve mitochondrial localization. Inside the tumor microenvironment, the catalyst catalyzes the conversion of endogenous hydrogen peroxide into superoxide anions (•O2−) and molecular oxygen, thereby disrupting the electron transport chain. This disruption creates an endogenous electron donor pool that fuels a self‑propagating oxidative‑stress cascade, dramatically increasing intracellular ROS levels without external stimuli. The design ensures that the catalytic activity is confined to mitochondria, minimizing collateral damage to healthy tissues.

A critical innovation of this system is the co‑delivery of chloroquine, a well‑known autophagy inhibitor. By blocking mitophagy, chloroquine prevents the clearance of dysfunctional mitochondria, allowing oxidative damage to accumulate and push cells toward apoptosis. This dual‑action strategy not only heightens tumor cell killing but also circumvents common resistance mechanisms linked to cellular repair pathways. As precision nanomedicine evolves, such organelle‑specific, self‑amplifying platforms could redefine therapeutic windows, offering oncologists more effective and safer options for hard‑to‑treat cancers.